Genflow Biosciences Share Discussion Threads

[kubera369] 24/10/2023 17:49

Can eric please tell us patient share holders what he is up to?Have you seen the pathetic paltry share price Eric ?The share price has nose dived since the U.S listing Where is the value for us share holders ?You have seen the share price plummet from over 10p to where it is today Can we have some answers Wd are the share holders and the supporters and so far we have been misled by you

[moneymunch] 21/10/2023 14:27

Hevolution Global Healthspan Summit 29th-30th November 2023


Igniting a Healthy Evolution

Unveiling the Global Healthspan Summit - Together We Thrive! Brought to you by the visionary Hevolution Foundation, this remarkable gathering of thought leaders promises to revolutionize how we view aging and healthspan science.


Where Visionaries Unite

Join us as we assemble the brightest minds, forward-thinking entrepreneurs, and influential stakeholders from across the globe! Scientists & Research Institutions, Innovators & entrepreneurs, investors, corporate leaders, international organizations & non-profits, and dignitaries will come together to facilitate action-based conversations and drive impact around catalyzing international collaboration in the emerging field of healthspan science.

Empowering Action Through Collaboration

No more passive discussions - it’s time for an honest, transformative change! Our Summit is all about action-driven conversations that will fuel groundbreaking research, cutting-edge entrepreneurship, and intelligent investments. Together, we’ll catalyze a global movement that will reshape the future of healthspan science.

A CRITICAL JUNCTION FOR CHANGE

We believe now is the decisive moment for decision-makers, investors, visionaries, governments, and researchers to unite. Let’s understand aging processes and elevate the discussion by exploring how to enhance the intersectional factors that promote healthy aging. 

UNLEASHING THE POWER OF ACTION

The Global Healthspan Summit is more than just a platform - it’s a catalyst for change! Across two pivotal days, leading minds will convene to discuss the latest insights, facilitating networking and knowledge exchange like never before.

[moneymunch] 21/10/2023 07:19

Dr Khan added: “We have also evaluated more than 150 companies around the world. We’ve already built a database with the companies that are active in the aging space globally. And we’ve received applications and letters of intent from scientists from around the world. Over 500 scientists have applied one way or another to collaborate with the Fund and get funding from us in this field.”

[moneymunch] 20/10/2023 18:37

Let's hope Genflow are on the radar of Hevolution and their $1 billion annual investment into promising early stage longevity biotechs.

Genflow's new collaboration with
Magnaetus Therapeutics have just been awarded $50,000 from the healthspan challenge and now go forward to the next stage of the challenge, where $1 million will be awarded in January for the most promising longevity therapies, followed by a grand prize of $5m in June. Gla ;-)

.

[moneymunch] 20/10/2023 18:27

Four years ago, by royal decree, Saudi Arabia’s Crown Prince Mohammed bin Salman pledged a vast financial investment - over a billion dollars a year - into research that would extend the healthy human lifespan, which led to the birth of the Kingdom’s ;Hevolution Foundation.

The Foundation - a global fund that aims to find and invest in innovative ways to “decelerate” the aging process and extend the number of years people live in good health - is heavily invested in academic research and biotech startups that promote longevity by slowing aging and combating age-related diseases.

.....

“We are an organization that’s helping all humanity,” she said, adding that the initiative aims to be the first non-profit to pursue age-related therapeutic breakthroughs. It is committed to funding global scientific discovery, and investing in private companies and entrepreneurs dedicated to advancing aging science.

“Hevolution wants to become a convener and to become a catalyst in the field and bridge the gap in the funding in terms of investment and in science, and the Hevolution Foundation has done multiple activities in the past year to ensure that we develop this convening and catalyst platform to move the healthspan science forward for the benefit of all of humanity.”

Dr al-Saud said therapeutics that extend a healthy human lifespan will redefine healthcare in the 21st century.

As of 2023, the non-profit organization has expanded outside the Kingdom’s borders – which houses its Riyadh headquarters – into its first international hub in Boston, Massachusetts. The US office makes it the country’s biggest hub for life sciences. It is eying up a further global hub in the United Kingdom by the end of the year and has plans for an Asia hub.

It has also, in the past 18 months, pledged $200 million for research into anti-aging, longevity biotech and healthy lifespan, a planned investment in two biotech companies, evaluated more than 150 companies across the globe as it eyes funding opportunities, is whittling down more than 500 grant applications from scientists around the world, has published the GCC’s first roadmap in healthy human lifespan, and is gearing to host the Kingdom’s first Global Healthspan Summit in November.

[moneymunch] 16/10/2023 21:29

Only a matter of time before Genflow receives similar attention from like minded investors .Gla :-)


LifeSpan Vision Ventures Makes 7th Investment in Pursuit of Longevity Mission


LifeSpan Vision Ventures
13 Oct, 2023,


"We are excited to unveil our seventh investment as we continue to forge ahead in the field of longevity," said Harry Robb, Analyst at LifeSpan Vision Ventures. "Our dedication to extending healthspan and enabling a longer, healthier, more fulfilling life for all remains at the core of our mission. We believe that the companies we invest in will play a pivotal role in driving forward the next wave of biotech solutions that promise a brighter future."

[moneymunch] 10/10/2023 09:31

Cheers Pie Chart, there's obviously lots of progress and exciting developments going on behind the scenes and plenty of news expected before year end on funding grants, Final Reports on 4 invivo evaluations on Sirt6 from Genflows four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France, and judging by the latest developments involving associated funding from a Pfizer backed biotech, there could be plenty of additional news to attract full market interest and appreciation. Genflow remains firmly under the radar and so the current bargain low is an absolute steel given the prospects and potential ahead. Gl :-)

[pie chart] 10/10/2023 09:08

Great insight and tie-ins. Exiting to be on the launchpad fully loaded for whenever this rocket shoots off.

[moneymunch] 10/10/2023 08:41

So in essence, VitaDAO, a longevity biotech company funded by Pfizer, is in turn funding Matrix Biosciences who have appointed Vera Gorbunova as their lead scientist, who is Genflow's number one lead collaborator from University of Rochester and her R&D into Sirt6, and VitaDAO are also funding Magnateus Biotech, who have just confirmed they're in collaboration with Genflow on their longevity R&D....All bodes well for Genflow imho, especially given how advanced they're are in progress towards their two human clinical trials for Nash & Werner Syndrome....Exciting times and very encouraging with Pfizer in the background. Gla holders:-)

[moneymunch] 10/10/2023 06:26

Pfizer connection and association.....Very interesting. Gla holders ;-)

[moneymunch] 10/10/2023 06:23

PFIZER connection. Gla ;-)


Pfizer-backed VitaDAO spins out biotech company

VitaDAO, which funds longevity research, announced the $300,000 financing of a biotechnology company, the DAO’s first such investment

[moneymunch] 10/10/2023 06:22

Global online DAO approves launch and financing of MatrixBio to optimal drug candidates for age-related diseases.

VitaDAO, the global online community driving early-stage longevity research through innovative funding collaborations has announced the launch of its very first biotech company – Matrix Biosciences. This significant milestone comes from a community-wide vote and approval in favor of a collaboration with Vera Gorbunova, PhD, Co-Chair of the University of Rochester’s Aging Research Center.

[moneymunch] 10/10/2023 06:12

Material news!!!??? Gla ;-)


2023 Healthy Longevity Global Innovator Summit

09/26/2023 8:00am


The evolving role of generative artificial intelligence in healthcare was front and center at the annual Healthy Longevity Global Innovator Summit, with experts expounding on its potential to help people live longer, healthier lives. Delivering the conference keynote was Peter Lee, Microsoft Corporate Vice President of Research and Incubations, who had a personal link to the topic of AI and medicine.

.........................


Developing therapeutic agents reverse ageing and metabolic decline

Cary Depel; Paul Baldock; Guy Barry | Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences
Competition Sponsor: US National Academy of Medicine
Awardee Year: 2023



Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.

To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.

Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.

[kubera369] 09/10/2023 14:37

Again hitting the all time lows Where is the news Eric that we have all been waiting for ?

[moneymunch] 09/10/2023 10:48

Fully funded until March 2025 and so amazed to see this fall to sub 2p, although presents a great opportunity to accumulate cheap shares with undoubted multi-bag potential in the coming weeks and months as good news is delivered. Gla holders..:-)

[pie chart] 09/10/2023 08:29

My buy showing as a sell also.

[iammrweald] 09/10/2023 07:57

More C&P needed Corporal Klump!
Transformational!! he he

[moneymunch] 09/10/2023 07:49

My £3k top up at 1.55p is showing as a sell. Gla :-)

[moneymunch] 06/10/2023 07:52

Plenty of material news to get the share price heading North expected in the coming weeks.

Eric confirmed in his recent interview they're in negotiations for two new non-dilutive funding grants expected to provide funding for an additional 3 years for 80% of their R&D, news of which could drop at anytime, followed by the Final Reports from their 4 academic collaborations which should be very well received.

Gla holders, the current bargain low offers tremendous UPside as progress is made and every chance of a major investor or JV partner in the Pipeline, given the huge promise of Sirt6's potency and importance in longevity, healthspan and multiple disease targets. ;-)


28/9/23

The Company continues to maintain a secure financial position and has sufficient cash reserves until March 2025. This is inclusive of grant funding which has been approved at the time of reporting and is due to be received in the coming months. The Company continues to seek further non-dilutive research grants which management will use to expedite specific phases of planned research and development.

......

The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.

These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.

[moneymunch] 05/10/2023 17:57

28/9/23 Half Year Report


-- The Group has expanded its intellectual property portfolio through a provisional patent application focussing on the ability to edit its SIRT6 gene. If granted, the patent will represent a significant breakthrough in the field of gene editing, with potential implications for longevity and other forms of gene therapy.

.......

1.20230018934

METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688
Applicant GENFLOW BIOSCIENCES SRL
Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

[pie chart] 05/10/2023 14:51

Sorry to hear that mate.

[iammrweald] 05/10/2023 12:14

The punters who bought at 12p and 5p obviously didnt!

[pie chart] 05/10/2023 09:29

Be fearful when others are greedy!

Be greedy when others are fearful!

The trick is to do the opposite of what your emotions tell you to do.

The fearful have driven the price down.

This is the time to be greedy.

This is the time accumulate & hold.

We all know the trajectory here.